Y-Biologics KRX:338840KOSDAQ
와이바이오로직스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days2
Articles tracked0since Sep 11
In Q2 2026, Y-Biologics reported revenue of ₩1.5bn, up 32.8% year on year, and an operating loss of ₩3.8bn. Y-Biologics (와이바이오로직스) appeared in 0 Korean news articles and 2 DART filings over the past seven days.
Filing signals 4 quarters of losses Screener
Y-Biologics quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩1.5bn | +32.8% | −₩3.8bn margin −244.9% | −₩7.8bn |
| Q1 2026 | ₩282m | -30.8% | −₩3.9bn | −₩4.3bn |
| Q4 2025 derived | ₩449m | -60.9% | −₩3.0bn | −₩35.1bn |
| Q3 2025 | ₩892m | -72.5% | −₩2.5bn margin −283.5% | −₩2.7bn |
| Q2 2025 | ₩1.2bn | +402.0% | −₩1.5bn margin −128.4% | −₩2.3bn |
| Q1 2025 | ₩407m | -64.4% | −₩2.3bn | −₩1.9bn |
| Q4 2024 derived | ₩1.1bn | +86.2% | −₩2.4bn margin −205.9% | −₩1.8bn |
| Q3 2024 | ₩3.2bn | +61.5% | −₩189m margin −5.8% | −₩151m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Y-Biologics top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Y-Biologics news Korean headlines
No articles yet.